Filter Results:
(176)
Show Results For
- All HBS Web
(176)
- People (1)
- News (51)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
Show Results For
- All HBS Web
(176)
- People (1)
- News (51)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
- Web
3 Technologies that Will Change the World - Course Catalog
promising a new, unimaginable future where humans capabilities could be enhanced, aging could be reversed, new forms of life created, and new custom designed materials could be grown rather than manufactured. Companies like Verve View Details
- 25 Apr 2014
- News
A revolution in healing
proteins. Moderna's mRNA Therapeutics gives patients' cells the code they need to begin creating their own proteins and antibodies to fight disease, allowing the body to heal itself. "We believe we have a chance to do something... View Details
- 23 Mar 2016
- News
Building a Biotech Business from Farmed Fish
Charlton Ames (MBA 1970) is chairman and vice president of business development for Sea Run Holdings, a virtual firm in Maine that develops innovative biologics and therapeutics from the blood of farmed salmon. In this video he explains... View Details
- 15 Sep 2020
- Blog Post
One Month into the New MS/MBA Biotech
perfectly for our August course. Initially, we planned to offer Lab Essentials as a hands-on lab course to immerse everyone back into the science, but with the coronavirus pandemic hitting globally, we realized that we had a unique opportunity to discuss the basic... View Details
Arjun Goyal
Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). Before co-founding Vida Ventures in 2017, Arjun was a life sciences... View Details
Keywords: Finance
Arjun Goyal
a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead),... View Details
- Fast Answer
Pharmaceuticals: Pipeline
Profiles cover detailed information such as alternative names, therapeutic uses, FDA actions and licensing changes, companies associated with development of the drug, etc. To begin a search, use the function BI PHRM DEX, select... View Details
- 23 Jan 2019
- News
The Promise of Personalized Medicine
as a biotechnology company, Myofinity Biosciences. Those two organizations have taken two different paths. They’re not connected. The 501(c)(3), Terry’s Foundation (now Cure Rare Disease), is doing something incredibly unprecedented. What that is, is it’s trying to... View Details
- 03 Nov 2016
- News
17 Ventures Join the Pagliuca Harvard Life Lab
Institute/HMS Nix – HBS, SEAS, Blavatnik Fellow PathoVax – HMS Piper Therapeutics – College, HBS Riparian Pharmaceuticals – College, SEAS Suono Bio – HMS UnNamed – HMS UrSure Inc. – HKS Vaxess Technologies, Inc. HBS, SEAS, HKS, HLS... View Details
- 24 Apr 2019
- Blog Post
2019 New Venture Competition Student and Alumni Journeys
Business School’s Rock Center for Entrepreneurship and Alumni Clubs & Associations. The competition is open to alumni with early-stage ventures.Grand prize: Blueland Runner up: X-COR Therapeutics Crowd favorite: Blueland View Video View Details
- 01 Dec 2013
- News
Innovation as Antidote
inspiration typically comes from a very human place. DART Therapeutics CEO Gene Williams (MBA 1987) ("Your Own Medicine"), for instance, told us about a revelation he had during a 2002 trip to Rotterdam to observe clinical trials for the... View Details
Keywords: Health, Social Assistance
- 11 Jun 2018
- Blog Post
Meet the 2018-2019 Blavatnik Fellows in Life Science Entrepreneurship
promising DMD treatments. While at business school, he worked to scale his nonprofit, Terry’s Foundation for Muscular Dystrophy, and helped advance therapeutics in the academic lab while raising awareness for DMD. Liz Kwo (MD/MBA 2011,... View Details
- Web
Mental Health | MBA
in a long-term therapeutic relationship while attending HBS. Students typically schedule an appointment with Suzy Conway to discuss their mental health needs to ascertain the level of service most appropriate to their needs and facilitate... View Details
- 17 Jun 2019
- Blog Post
Why I Would Have Applied to the MS/MBA Biotechnology: Life Sciences Program
Kristina Wang (MBA 2020) is an MBA student at HBS who just completed her first year and is currently interning at Denali Therapeutics before her second year. I did not expect myself to become interested in biotechnology. Growing up in... View Details
- 01 Jun 2000
- News
Managing the Map
Health (NIH) undertook the Human Genome Project, an effort to map the extraordinarily intricate chemical composition of the human genome. Scientists have long believed that understanding the vast genetic code underlying all human life will enable the development of new... View Details
Keywords: Peter K. Jacobs
- 01 Oct 2021
- News
New Biotech Joint Degree Program Kicks Off
Frontiers in Therapeutics is an ethics and management course on the world’s most pressing unsolved medical challenges. The impetus for the program came from recognizing that the biotech sector needs strong, ethical leaders who can break... View Details
- 25 Feb 2021
- News
Building Hope
a doctor’s office for a dose of ketamine and remains under the care of medical professionals for about an hour while the ketamine does its thing. Ketamine can induce out-of-body experiences, so a safe setting is an important part of the View Details
Keywords: Daniel Morrell
- 01 Dec 2019
- News
The Race Against Resistance
with the rise of antibiotic-resistant superbugs. “We are approaching a cliff,” says Anna Diaz Triola (MBA 2000), vice president of marketing at Summit Therapeutics in Cambridge, Massachusetts, which is part of a cohort of small pharma... View Details
Keywords: Lisa Scanlon Mogolov
- 16 May 2017
- Blog Post
Making the Move into Digital Health and Software Engineering
the engineering team at Akili Interactive, a start-up in Boston that is developing a digital therapeutic for ADHD. I cross-registered across the river in MIT's Revolutionary Ventures class, which is part of the Synthetic Neurobiology... View Details
- 04 Sep 2019
- News
Accelerating Scientific Discovery
ask their scientists about therapeutics they are developing as their companies grapple with both clinical trial successes and failures. Classes also will focus on the most promising advances, including CRISPR-Cas9, base editing, RNA... View Details
Keywords: Jennifer Gillespie